1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3.
Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7.
Assumptions
and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical
Trials
5.2. Completed Clinical
Trials
5.3. Terminated Clinical
Trials
5.4. Breakdown of
Pipeline, By Development Phase
5.5. Breakdown of
Pipeline, By Status
5.6. Breakdown of
Pipeline, By Site Analysis
5.7. Breakdown of
Pipeline, By Region
5.8.
Clinical Trials Heat Map
6. Global
Neuroendocrine Tumor Treatment Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Product Analysis
(Somatostatin Analogs (SSA), Targeted Therapy, Others)
6.2.2. By
Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
6.2.3. By End User
(Hospitals & Clinics, Ambulatory Care Centers, Others)
6.2.4. By
Region
6.2.5. By Company (2022)
6.3. Market
Map
6.3.1. By
Product Analysis
6.3.2. By
Site Analysis
6.3.3. By
End User
6.3.4. By
Region
7. Asia-Pacific
Neuroendocrine Tumor Treatment Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Product Analysis (Somatostatin
Analogs (SSA), Targeted Therapy, Others)
7.2.2. By Site Analysis (Lungs,
Pancreas, Colon, Small Intestine, Others)
7.2.3. By End User (Hospitals
& Clinics, Ambulatory Care Centers, Others)
7.2.4.
By Country
7.3.
Asia-Pacific: Country Analysis
7.3.1.
China Neuroendocrine Tumor Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Product Analysis
7.3.1.2.2.
By Site Analysis
7.3.1.2.3.
By End User
7.3.2.
India Neuroendocrine Tumor Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Product Analysis
7.3.2.2.2.
By Site Analysis
7.3.2.2.3.
By End User
7.3.3.
Japan Neuroendocrine Tumor Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Product Analysis
7.3.3.2.2.
By Site Analysis
7.3.3.2.3.
By End User
7.3.4.
South Korea Neuroendocrine Tumor Treatment Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Product Analysis
7.3.4.2.2.
By Site Analysis
7.3.4.2.3.
By End User
7.3.5.
Australia Neuroendocrine Tumor Treatment Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Product Analysis
7.3.5.2.2.
By Site Analysis
7.3.5.2.3.
By End User
8. Europe
Neuroendocrine Tumor Treatment Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Product Analysis (Somatostatin
Analogs (SSA), Targeted Therapy, Others)
8.2.2. By Site Analysis (Lungs,
Pancreas, Colon, Small Intestine, Others)
8.2.3.
By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
8.2.4.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Neuroendocrine Tumor Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Product Analysis
8.3.1.2.2.
By Site Analysis
8.3.1.2.3.
By End User
8.3.2.
Germany Neuroendocrine Tumor Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Product Analysis
8.3.2.2.2.
By Site Analysis
8.3.2.2.3.
By End User
8.3.3.
United Kingdom Neuroendocrine Tumor Treatment Market
Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Product Analysis
8.3.3.2.2.
By Site Analysis
8.3.3.2.3.
By End User
8.3.4.
Italy Neuroendocrine Tumor Treatment Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Product Analysis
8.3.4.2.2.
By Site Analysis
8.3.4.2.3.
By End User
8.3.5.
Spain Neuroendocrine Tumor Treatment Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Product Analysis
8.3.5.2.2.
By Site Analysis
8.3.5.2.3.
By End User
9. North America
Neuroendocrine Tumor Treatment Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Product Analysis (Somatostatin
Analogs (SSA), Targeted Therapy, Others)
9.2.2. By Site Analysis (Lungs,
Pancreas, Colon, Small Intestine, Others)
9.2.3.
By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
9.2.4.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States Neuroendocrine Tumor Treatment Market
Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Product Analysis
9.3.1.2.2.
By Site Analysis
9.3.1.2.3.
By End User
9.3.2.
Mexico Neuroendocrine Tumor Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Product Analysis
9.3.2.2.2.
By Site Analysis
9.3.2.2.3.
By End User
9.3.3.
Canada Neuroendocrine Tumor Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Product Analysis
9.3.3.2.2.
By Site Analysis
9.3.3.2.3.
By End User
10. South America
Neuroendocrine Tumor Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Product Analysis (Somatostatin
Analogs (SSA), Targeted Therapy, Others)
10.2.2. By Site Analysis (Lungs,
Pancreas, Colon, Small Intestine, Others)
10.2.3.
By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
10.2.4.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Neuroendocrine Tumor Treatment Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Product Analysis
10.3.1.2.2.
By Site Analysis
10.3.1.2.3.
By End User
10.3.2.
Argentina Neuroendocrine Tumor Treatment Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Product Analysis
10.3.2.2.2.
By Site Analysis
10.3.2.2.3.
By End User
10.3.3.
Colombia Neuroendocrine Tumor Treatment Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Product Analysis
10.3.3.2.2.
By Site Analysis
10.3.3.2.3.
By End User
11. Middle East and
Africa Neuroendocrine Tumor Treatment Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1. By Product Analysis (Somatostatin
Analogs (SSA), Targeted Therapy, Others)
11.2.2. By Site Analysis (Lungs,
Pancreas, Colon, Small Intestine, Others)
11.2.3.
By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
11.2.4.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Neuroendocrine Tumor Treatment Market
Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Product Analysis
11.3.1.2.2.
By Site Analysis
11.3.1.2.3.
By End User
11.3.2.
Saudi Arabia Neuroendocrine Tumor Treatment Market
Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Product Analysis
11.3.2.2.2.
By Site Analysis
11.3.2.2.3.
By End User
11.3.3.
UAE Neuroendocrine Tumor Treatment Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Product Analysis
11.3.3.2.2.
By Site Analysis
11.3.3.2.3.
By End User
12. Market Dynamics
12.1.
Drivers
12.1.1.
Developments and Approval of Novel Drugs
12.1.2.
Use of Artificial Intelligence (AI) in Treatment Techniques
12.1.3.
Increased Government and Company’s’ Initiatives
12.2.
Challenges
12.2.1.
High Cost of the Treatment
12.2.2.
Associated Side Effects of the Treatment
12.2.3.
Stringent Regulatory Framework
13. Market Trends &
Developments
13.1.
Upcoming Patient Assistance Programs (PAPs)
13.2.
Ongoing Clinical Trials and R&D Programs
13.3.
Adoption of Next-Generation Sequencing Techniques
14. Competitive
Landscape
14.1.
Business Overview
14.2.
Company Snapshot
14.3.
Products & Services
14.4.
Financials (As Reported)
14.5.
Recent Developments
14.6.
SWOT Analysis
14.6.1.
F Hoffmann-La Roche
AG
14.6.2.
Bristol-Myers Squibb
Co
14.6.3.
Eli Lilly & Co
14.6.4.
Novartis AG
14.6.5.
Pfizer Inc
14.6.6.
Amgen Inc
14.6.7.
Exelixis Inc
14.6.8.
Teva Pharmaceutical
Industries Ltd
14.6.9.
AVEO Pharmaceuticals
Inc
14.6.10.
Hutchison MediPharma
Ltd
15. Strategic Recommendations